EA201791179A1 - Дейтерированный триазолопиридазин в качестве модулятора киназы - Google Patents
Дейтерированный триазолопиридазин в качестве модулятора киназыInfo
- Publication number
- EA201791179A1 EA201791179A1 EA201791179A EA201791179A EA201791179A1 EA 201791179 A1 EA201791179 A1 EA 201791179A1 EA 201791179 A EA201791179 A EA 201791179A EA 201791179 A EA201791179 A EA 201791179A EA 201791179 A1 EA201791179 A1 EA 201791179A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- compounds
- met
- cell
- subject
- present
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Настоящее изобретение относится к триазолопиридазиновому соединению формулы (I)его N-оксидам, фармацевтически приемлемым солям и сольватам, где D представляет собой дейтерий, применению таких соединений в качестве модуляторов протеинтирозинкиназы, в частности ингибиторов c-Met, применению таких соединений для уменьшения или ингибирования киназной активности c-Met в клетке или субъекте и модулирования экспрессии c-Met в клетке или субъекте и применению таких соединений для предупреждения или лечения у субъекта нарушения, связанного с пролиферацией клеток, и/или нарушений, связанных с c-Met. Настоящее изобретение дополнительно относится к фармацевтическим композициям, содержащим соединения по настоящему изобретению, и к способам лечения состояний, таких как формы рака, и других нарушений, связанных с пролиферацией клеток.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14196387 | 2014-12-04 | ||
| EP14196585 | 2014-12-05 | ||
| PCT/EP2015/078525 WO2016087586A1 (en) | 2014-12-04 | 2015-12-03 | A deuterated triazolopyridazine as a kinase modulator |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201791179A1 true EA201791179A1 (ru) | 2017-09-29 |
| EA033193B1 EA033193B1 (ru) | 2019-09-30 |
Family
ID=54771127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201791179A EA033193B1 (ru) | 2014-12-04 | 2015-12-03 | Дейтерированный триазолопиридазин в качестве модулятора киназы |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US10138246B2 (ru) |
| EP (1) | EP3227296B1 (ru) |
| JP (1) | JP6795502B2 (ru) |
| KR (1) | KR102643179B1 (ru) |
| CN (1) | CN107108632B (ru) |
| AU (1) | AU2015357085B2 (ru) |
| BR (1) | BR112017010849B1 (ru) |
| CA (1) | CA2968294C (ru) |
| DK (1) | DK3227296T3 (ru) |
| EA (1) | EA033193B1 (ru) |
| ES (1) | ES2795666T3 (ru) |
| HU (1) | HUE050285T2 (ru) |
| IL (1) | IL252356B (ru) |
| MX (1) | MX2017007114A (ru) |
| MY (1) | MY183207A (ru) |
| PL (1) | PL3227296T3 (ru) |
| PT (1) | PT3227296T (ru) |
| SG (1) | SG11201704078XA (ru) |
| SI (1) | SI3227296T1 (ru) |
| TW (1) | TWI695837B (ru) |
| WO (1) | WO2016087586A1 (ru) |
| ZA (1) | ZA201703386B (ru) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI695837B (zh) * | 2014-12-04 | 2020-06-11 | 比利時商健生藥品公司 | 作為激酶調節劑之三唑並嗒 |
| CN106279176B (zh) * | 2015-06-11 | 2020-09-08 | 中国科学院上海药物研究所 | 氘代的3-[(6-喹啉基)二氟甲基]-6-[(1-甲基)-4-吡唑基][1,2,4]三唑并[4,3-b]哒嗪及其应用 |
| WO2019161320A1 (en) * | 2018-02-17 | 2019-08-22 | Apollomics Inc. | Cancer treatment using combination of neutrophil modulator with modulator of immune checkpoint |
| WO2022140528A1 (en) * | 2020-12-23 | 2022-06-30 | Genzyme Corporation | Deuterated colony stimulating factor-1 receptor (csf-1r) inhibitors |
| EP4267573A1 (en) | 2020-12-23 | 2023-11-01 | Genzyme Corporation | Deuterated colony stimulating factor-1 receptor (csf-1r) inhibitors |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1306095A3 (en) | 1992-03-05 | 2003-06-25 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
| US5474765A (en) | 1992-03-23 | 1995-12-12 | Ut Sw Medical Ctr At Dallas | Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells |
| EP0822788B1 (en) | 1995-04-19 | 2002-09-04 | Schneider (Usa) Inc. | Drug release coated stent |
| CA2372053C (en) | 1999-04-28 | 2008-09-02 | Board Of Regents, The University Of Texas System | Compositions and methods for cancer treatment by selectively inhibiting vegf |
| US6776796B2 (en) | 2000-05-12 | 2004-08-17 | Cordis Corportation | Antiinflammatory drug and delivery device |
| AP3433A (en) * | 2005-12-21 | 2015-10-31 | Janssen Pharmaceutica Nv | Triazolopyridazines as tyrosine kinase modultors |
| JP5548123B2 (ja) * | 2007-06-21 | 2014-07-16 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ６−｛ジフルオロ［６−（１−メチル−１Ｈ−ピラゾル−４−イル）［１，２，４］トリアゾロ［４，３−ｂ］ピリダジン−３−イル］メチル｝キノリンの多形および水和物の形態、塩、ならびに製造方法 |
| DE102007032507A1 (de) | 2007-07-12 | 2009-04-02 | Merck Patent Gmbh | Pyridazinonderivate |
| PA8792501A1 (es) | 2007-08-09 | 2009-04-23 | Sanofi Aventis | Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met. |
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| GB201118656D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| TWI695837B (zh) * | 2014-12-04 | 2020-06-11 | 比利時商健生藥品公司 | 作為激酶調節劑之三唑並嗒 |
-
2015
- 2015-12-02 TW TW104140256A patent/TWI695837B/zh active
- 2015-12-03 PL PL15804143T patent/PL3227296T3/pl unknown
- 2015-12-03 EA EA201791179A patent/EA033193B1/ru unknown
- 2015-12-03 HU HUE15804143A patent/HUE050285T2/hu unknown
- 2015-12-03 WO PCT/EP2015/078525 patent/WO2016087586A1/en active Application Filing
- 2015-12-03 BR BR112017010849-6A patent/BR112017010849B1/pt active IP Right Grant
- 2015-12-03 SI SI201531234T patent/SI3227296T1/sl unknown
- 2015-12-03 CN CN201580065572.0A patent/CN107108632B/zh active Active
- 2015-12-03 MX MX2017007114A patent/MX2017007114A/es unknown
- 2015-12-03 PT PT158041434T patent/PT3227296T/pt unknown
- 2015-12-03 EP EP15804143.4A patent/EP3227296B1/en active Active
- 2015-12-03 ES ES15804143T patent/ES2795666T3/es active Active
- 2015-12-03 US US15/531,780 patent/US10138246B2/en active Active
- 2015-12-03 SG SG11201704078XA patent/SG11201704078XA/en unknown
- 2015-12-03 AU AU2015357085A patent/AU2015357085B2/en active Active
- 2015-12-03 KR KR1020177018365A patent/KR102643179B1/ko active IP Right Grant
- 2015-12-03 DK DK15804143.4T patent/DK3227296T3/da active
- 2015-12-03 CA CA2968294A patent/CA2968294C/en active Active
- 2015-12-03 MY MYPI2017701732A patent/MY183207A/en unknown
- 2015-12-03 JP JP2017530188A patent/JP6795502B2/ja active Active
-
2017
- 2017-05-16 ZA ZA2017/03386A patent/ZA201703386B/en unknown
- 2017-05-17 IL IL252356A patent/IL252356B/en active IP Right Grant
-
2018
- 2018-10-04 US US16/152,088 patent/US10464939B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019501321B1 (en) | Use of pyrazolopyrimidine derivatives for the treatment of pi3k-delta related disorders | |
| EA201891191A1 (ru) | 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения | |
| EA201990665A1 (ru) | Регуляторы hpk1 на основе производных пиразолопиридина и их применение для лечения рака | |
| EA201790317A1 (ru) | Ингибиторы smyd | |
| EA201791018A1 (ru) | Производные 6-амино-7-бицикло-7-деазапурина в качестве ингибиторов протеинкиназы | |
| EA201592068A1 (ru) | Ингибиторы энхансера zeste гомолога 2 | |
| EA201690752A1 (ru) | Ингибиторы g12c kras | |
| EA201692079A1 (ru) | Ингибиторы лизин-специфической деметилазы-1 | |
| EA201790599A1 (ru) | Соединения и композиции в качестве ингибиторов киназ | |
| EA201290103A1 (ru) | Гетероциклические соединения и их использование | |
| EA201591753A1 (ru) | 3-пиримидин-4-илоксазолидин-2-оны в качестве ингибиторов мутантного idh | |
| EA201490891A1 (ru) | Пиридопиразины, обладающие противораковой активностью через ингибирование fgfr киназ | |
| MY159523A (en) | Triazolopyridazines as tyrosine kinase modulators | |
| EA201791179A1 (ru) | Дейтерированный триазолопиридазин в качестве модулятора киназы | |
| PH12020500343A1 (en) | Pyruvate kinase activators for use in treating blood disorders | |
| EA201491747A1 (ru) | Замещенные пиридопиримидиновые соединения и их применение в качестве flt3 ингибиторов | |
| MX2017002986A (es) | Compuestos de piperidina sustituidos. | |
| PH12016502353A1 (en) | Pharmaceutical composition | |
| EA201790908A1 (ru) | Новые производные тиенопиримидина в качестве ингибиторов nik | |
| EA201992137A1 (ru) | ПИРИМИДОПИРИМИДИНОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗЫ Wee-1 | |
| TW201613577A (en) | Pharmaceutical combinations | |
| JOP20220107A1 (ar) | مثبطات egfr تفارغية وطرق استخدامها | |
| MX2020003126A (es) | Derivados de iminopirimidina ciclicos como inhibidores de cinasa. | |
| PH12016500735A1 (en) | Substituted pyrimidine compounds and their use as syk inhibitors | |
| MX2018007517A (es) | Compuestos triciclicos y composiciones como inhibidores de quinasa. |